Pub Date : 2022-05-01Epub Date: 2021-11-18DOI: 10.1136/ebmental-2021-300317
Andrew Healey, Ruth Verhey, Iris Mosweu, Janet Boadu, Dixon Chibanda, Charmaine Chitiyo, Brad Wagenaar, Hugo Senra, Ephraim Chiriseri, Sandra Mboweni, Ricardo Araya
Background: Task-sharing treatment approaches offer a pragmatic approach to treating common mental disorders in low-income and middle-income countries (LMICs). The Friendship Bench (FB), developed in Zimbabwe with increasing adoption in other LMICs, is one example of this type of treatment model using lay health workers (LHWs) to deliver treatment.
Objective: To consider the level of treatment coverage required for a recent scale-up of the FB in Zimbabwe to be considered cost-effective.
Methods: A modelling-based deterministic threshold analysis conducted within a 'cost-utility' framework using a recommended cost-effectiveness threshold.
Findings: The FB would need to treat an additional 3413 service users (10 per active LHW per year) for its scale-up to be considered cost-effective. This assumes a level of treatment effect observed under clinical trial conditions. The associated incremental cost-effectiveness ratio was $191 per year lived with disability avoided, assuming treatment coverage levels reported during 2020. The required treatment coverage for a cost-effective outcome is within the level of treatment coverage observed during 2020 and remained so even when assuming significantly compromised levels of treatment effect.
Conclusions: The economic case for a scaled-up delivery of the FB appears convincing in principle and its adoption at scale in LMIC settings should be given serious consideration.
Clinical implications: Further evidence on the types of scale-up strategies that are likely to offer an effective and cost-effective means of sustaining required levels of treatment coverage will help focus efforts on approaches to scale-up that optimise resources invested in task-sharing programmes.
{"title":"Economic threshold analysis of delivering a task-sharing treatment for common mental disorders at scale: the Friendship Bench, Zimbabwe.","authors":"Andrew Healey, Ruth Verhey, Iris Mosweu, Janet Boadu, Dixon Chibanda, Charmaine Chitiyo, Brad Wagenaar, Hugo Senra, Ephraim Chiriseri, Sandra Mboweni, Ricardo Araya","doi":"10.1136/ebmental-2021-300317","DOIUrl":"10.1136/ebmental-2021-300317","url":null,"abstract":"<p><strong>Background: </strong>Task-sharing treatment approaches offer a pragmatic approach to treating common mental disorders in low-income and middle-income countries (LMICs). The Friendship Bench (FB), developed in Zimbabwe with increasing adoption in other LMICs, is one example of this type of treatment model using lay health workers (LHWs) to deliver treatment.</p><p><strong>Objective: </strong>To consider the level of treatment coverage required for a recent scale-up of the FB in Zimbabwe to be considered cost-effective.</p><p><strong>Methods: </strong>A modelling-based deterministic threshold analysis conducted within a 'cost-utility' framework using a recommended cost-effectiveness threshold.</p><p><strong>Findings: </strong>The FB would need to treat an additional 3413 service users (10 per active LHW per year) for its scale-up to be considered cost-effective. This assumes a level of treatment effect observed under clinical trial conditions. The associated incremental cost-effectiveness ratio was $191 per year lived with disability avoided, assuming treatment coverage levels reported during 2020. The required treatment coverage for a cost-effective outcome is within the level of treatment coverage observed during 2020 and remained so even when assuming significantly compromised levels of treatment effect.</p><p><strong>Conclusions: </strong>The economic case for a scaled-up delivery of the FB appears convincing in principle and its adoption at scale in LMIC settings should be given serious consideration.</p><p><strong>Clinical implications: </strong>Further evidence on the types of scale-up strategies that are likely to offer an effective and cost-effective means of sustaining required levels of treatment coverage will help focus efforts on approaches to scale-up that optimise resources invested in task-sharing programmes.</p>","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":" ","pages":"47-53"},"PeriodicalIF":6.6,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39903963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-28DOI: 10.1136/ebmental-2021-300409
F. Jollant, K. Goueslard, K. Hawton, C. Quantin
Background There is limited recent information regarding the risk of self-harm, somatic disorders and premature mortality following discharge from psychiatric hospital in young people. Objective To measure these risks in young people discharged from a psychiatric hospital as compared with both non-affected controls and non-hospitalised affected controls. Methods Data were extracted from the French national health records. Cases were compared with two control groups. Cases: all individuals aged 12–24 years, hospitalised in psychiatry in France in 2013–2014. Non-affected controls: matched for age and sex with cases, not hospitalised in psychiatry and no identification of a mental disorder in 2008–2014. Affected controls: unmatched youths identified with a mental disorder between 2008 and 2014, never hospitalised in psychiatry. Follow-up of 3 years. Logistic regression analyses were conducted with these confounding variables: age, sex, past hospitalisation for self-harm, past somatic disorder diagnosis. Findings The studied population comprised 73 300 hospitalised patients (53.6% males), 219 900 non-affected controls and 9 683 affected controls. All rates and adjusted risks were increased in hospitalised patients versus both non-affected and affected controls regarding a subsequent hospitalisation for self-harm (HR=105.5, 95% CIs (89.5 to 124.4) and HR=1.5, 95% CI (1.4 to 1.6)), a somatic disorder diagnosis (HR=4.1, 95% CI (3.9–4.1) and HR=1.4, 95% CI (1.3–1.5)), all-cause mortality (HR=13.3, 95% CI (10.6–16.7) and HR=2.2, 95% CI (1.5–3.0)) and suicide (HR=9.2, 95% CI (4.3–19.8) and HR=1.7, 95% CI (1.0–2.9)). Conclusions The first 3 years following psychiatric hospital admission of young people is a period of high risk for self-harm, somatic disorders and premature mortality. Clinical implications Attention to these negative outcomes urgently needs to be incorporated in aftercare policies.
{"title":"Self-harm, somatic disorders and mortality in the 3 years following a hospitalisation in psychiatry in adolescents and young adults","authors":"F. Jollant, K. Goueslard, K. Hawton, C. Quantin","doi":"10.1136/ebmental-2021-300409","DOIUrl":"https://doi.org/10.1136/ebmental-2021-300409","url":null,"abstract":"Background There is limited recent information regarding the risk of self-harm, somatic disorders and premature mortality following discharge from psychiatric hospital in young people. Objective To measure these risks in young people discharged from a psychiatric hospital as compared with both non-affected controls and non-hospitalised affected controls. Methods Data were extracted from the French national health records. Cases were compared with two control groups. Cases: all individuals aged 12–24 years, hospitalised in psychiatry in France in 2013–2014. Non-affected controls: matched for age and sex with cases, not hospitalised in psychiatry and no identification of a mental disorder in 2008–2014. Affected controls: unmatched youths identified with a mental disorder between 2008 and 2014, never hospitalised in psychiatry. Follow-up of 3 years. Logistic regression analyses were conducted with these confounding variables: age, sex, past hospitalisation for self-harm, past somatic disorder diagnosis. Findings The studied population comprised 73 300 hospitalised patients (53.6% males), 219 900 non-affected controls and 9 683 affected controls. All rates and adjusted risks were increased in hospitalised patients versus both non-affected and affected controls regarding a subsequent hospitalisation for self-harm (HR=105.5, 95% CIs (89.5 to 124.4) and HR=1.5, 95% CI (1.4 to 1.6)), a somatic disorder diagnosis (HR=4.1, 95% CI (3.9–4.1) and HR=1.4, 95% CI (1.3–1.5)), all-cause mortality (HR=13.3, 95% CI (10.6–16.7) and HR=2.2, 95% CI (1.5–3.0)) and suicide (HR=9.2, 95% CI (4.3–19.8) and HR=1.7, 95% CI (1.0–2.9)). Conclusions The first 3 years following psychiatric hospital admission of young people is a period of high risk for self-harm, somatic disorders and premature mortality. Clinical implications Attention to these negative outcomes urgently needs to be incorporated in aftercare policies.","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":"25 1","pages":"177 - 184"},"PeriodicalIF":5.2,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49431166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-04DOI: 10.1136/ebmental-2021-300355
R. Joseph, R. Jack, R. Morriss, R. Knaggs, D. Butler, C. Hollis, J. Hippisley-Cox, C. Coupland
Background Studies report an increased risk of self-harm or suicide in people prescribed mirtazapine compared with other antidepressants. Objectives To compare the risk of serious self-harm in people prescribed mirtazapine versus other antidepressants as second-line treatments. Design and setting Cohort study using anonymised English primary care electronic health records, hospital admission data and mortality data with study window 1 January 2005 to 30 November 2018. Participants 24 516 people diagnosed with depression, aged 18–99 years, initially prescribed a selective serotonin reuptake inhibitor (SSRI) and then prescribed mirtazapine, a different SSRI, amitriptyline or venlafaxine. Main outcome measures Hospitalisation or death due to deliberate self-harm. Age–sex standardised rates were calculated and survival analyses were performed using inverse probability of treatment weighting to account for baseline covariates. Results Standardised rates of serious self-harm ranged from 3.8/1000 person-years (amitriptyline) to 14.1/1000 person-years (mirtazapine). After weighting, the risk of serious self-harm did not differ significantly between the mirtazapine group and the SSRI or venlafaxine groups (HRs (95% CI) 1.18 (0.84 to 1.65) and 0.85 (0.51 to 1.41) respectively). The risk was significantly higher in the mirtazapine than the amitriptyline group (3.04 (1.36 to 6.79)) but was attenuated after adjusting for dose. Conclusions There was no evidence for a difference in risk between mirtazapine and SSRIs or venlafaxine after accounting for baseline characteristics. The higher risk in the mirtazapine versus the amitriptyline group might reflect residual confounding if amitriptyline is avoided in people considered at risk of self-harm. Clinical implications Addressing baseline risk factors and careful monitoring might improve outcomes for people at risk of serious self-harm.
{"title":"Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records","authors":"R. Joseph, R. Jack, R. Morriss, R. Knaggs, D. Butler, C. Hollis, J. Hippisley-Cox, C. Coupland","doi":"10.1136/ebmental-2021-300355","DOIUrl":"https://doi.org/10.1136/ebmental-2021-300355","url":null,"abstract":"Background Studies report an increased risk of self-harm or suicide in people prescribed mirtazapine compared with other antidepressants. Objectives To compare the risk of serious self-harm in people prescribed mirtazapine versus other antidepressants as second-line treatments. Design and setting Cohort study using anonymised English primary care electronic health records, hospital admission data and mortality data with study window 1 January 2005 to 30 November 2018. Participants 24 516 people diagnosed with depression, aged 18–99 years, initially prescribed a selective serotonin reuptake inhibitor (SSRI) and then prescribed mirtazapine, a different SSRI, amitriptyline or venlafaxine. Main outcome measures Hospitalisation or death due to deliberate self-harm. Age–sex standardised rates were calculated and survival analyses were performed using inverse probability of treatment weighting to account for baseline covariates. Results Standardised rates of serious self-harm ranged from 3.8/1000 person-years (amitriptyline) to 14.1/1000 person-years (mirtazapine). After weighting, the risk of serious self-harm did not differ significantly between the mirtazapine group and the SSRI or venlafaxine groups (HRs (95% CI) 1.18 (0.84 to 1.65) and 0.85 (0.51 to 1.41) respectively). The risk was significantly higher in the mirtazapine than the amitriptyline group (3.04 (1.36 to 6.79)) but was attenuated after adjusting for dose. Conclusions There was no evidence for a difference in risk between mirtazapine and SSRIs or venlafaxine after accounting for baseline characteristics. The higher risk in the mirtazapine versus the amitriptyline group might reflect residual confounding if amitriptyline is avoided in people considered at risk of self-harm. Clinical implications Addressing baseline risk factors and careful monitoring might improve outcomes for people at risk of serious self-harm.","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":"25 1","pages":"169 - 176"},"PeriodicalIF":5.2,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43538094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01DOI: 10.1136/ebmental-2021-300291
Ita Fitzgerald, Jean O'Connell, Dolores Keating, Caroline Hynes, Stephen McWilliams, Erin K Crowley
Background: Adjunctive metformin is the most well-studied intervention in the pharmacological management of antipsychotic-induced weight gain (AIWG). Although a relatively unaddressed area, among guidelines recommending consideration of metformin, prescribing information that would facilitate its applied use by clinicians, for example, provision of a dose titration schedule is absent. Moreover, recommendations differ regarding metformin's place in the hierarchy of management options. Both represent significant barriers to the applied, evidence-based use of metformin for this indication.
Objective: To produce a guideline solely dedicated to the optimised use of metformin in AIWG management, using internationally endorsed guideline methodology.
Methods: A list of guideline key health questions (KHQs) was produced. It was agreed that individual recommendations would be 'adopted or adapted' from current guidelines and/or developed de novo, in the case of unanswered questions. A systematic literature review (2008-2020) was undertaken to identify published guidelines and supporting (or more recent) research evidence. Quality appraisal was undertaken using the Appraisal of Guidelines Research and Evaluation II tool, A Measurement Tool to Assess Systematic Reviews (AMSTAR) assessment,and the Cochrane Risk of Bias 2 tool, where appropriate. Assessment of evidence certainty and recommendation development was undertaken using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology.
Findings: We confirmed that no published guideline-of appropriate quality, solely dedicated to the use of metformin to manage AIWG was available. Recommendations located within other guidelines inadequately addressed our KHQs.
Conclusion: All 11 recommendations and 7 supporting good practice developed here were formulated de novo.
Clinical implications: These recommendations build on the number and quality of recommendations in this area, and facilitate the optimised use of metformin when managing AIWG.
{"title":"Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology.","authors":"Ita Fitzgerald, Jean O'Connell, Dolores Keating, Caroline Hynes, Stephen McWilliams, Erin K Crowley","doi":"10.1136/ebmental-2021-300291","DOIUrl":"https://doi.org/10.1136/ebmental-2021-300291","url":null,"abstract":"<p><strong>Background: </strong>Adjunctive metformin is the most well-studied intervention in the pharmacological management of antipsychotic-induced weight gain (AIWG). Although a relatively unaddressed area, among guidelines recommending consideration of metformin, prescribing information that would facilitate its applied use by clinicians, for example, provision of a dose titration schedule is absent. Moreover, recommendations differ regarding metformin's place in the hierarchy of management options. Both represent significant barriers to the applied, evidence-based use of metformin for this indication.</p><p><strong>Objective: </strong>To produce a guideline solely dedicated to the optimised use of metformin in AIWG management, using internationally endorsed guideline methodology.</p><p><strong>Methods: </strong>A list of guideline key health questions (KHQs) was produced. It was agreed that individual recommendations would be 'adopted or adapted' from current guidelines and/or developed de novo, in the case of unanswered questions. A systematic literature review (2008-2020) was undertaken to identify published guidelines and supporting (or more recent) research evidence. Quality appraisal was undertaken using the Appraisal of Guidelines Research and Evaluation II tool, A Measurement Tool to Assess Systematic Reviews (AMSTAR) assessment,and the Cochrane Risk of Bias 2 tool, where appropriate. Assessment of evidence certainty and recommendation development was undertaken using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology.</p><p><strong>Findings: </strong>We confirmed that no published guideline-of appropriate quality, solely dedicated to the use of metformin to manage AIWG was available. Recommendations located within other guidelines inadequately addressed our KHQs.</p><p><strong>Conclusion: </strong>All 11 recommendations and 7 supporting good practice developed here were formulated de novo.</p><p><strong>Clinical implications: </strong>These recommendations build on the number and quality of recommendations in this area, and facilitate the optimised use of metformin when managing AIWG.</p>","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":"25 1","pages":"15-22"},"PeriodicalIF":5.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10269964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01Epub Date: 2021-09-12DOI: 10.1136/ebmental-2021-300307
Viktor H Ahlqvist, Lucas D Ekström, Egill Jónsson-Bachmann, Per Tynelius, Paul Madley-Dowd, Martin Neovius, Cecilia Magnusson, Daniel Berglind
Background: A relationship between caesarean section and offspring cognitive ability has been described, but data are limited, and a large-scale study is needed.
Objective: To determine the relationship between mode of delivery and general cognitive ability.
Methods: A cohort of 579 244 singleton males, born between 1973 and 1987 who conscripted before 2006, were identified using the Swedish population-based registries. Their mode of delivery was obtained from the Swedish Medical Birth registry. The outcome measure was a normalised general cognitive test battery (mean 100, SD 15) performed at military conscription at around age 18.
Findings: Males born by caesarean section performed poorer compared with those born vaginally (mean score 99.3 vs 100.1; adjusted mean difference -0.84; 95% CI -0.97 to -0.72; p<0.001). Both those born by elective (99.3 vs 100.2; -0.92; 95% CI -1.24 to -0.60; p<0.001) and non-elective caesarean section (99.2 vs 100.2; -1.03; 95% CI -1.34 to -0.72; p=0.001), performed poorer than those born vaginally. In sibling analyses, the association was attenuated to the null (100.9 vs 100.8; 0.07; 95% CI -0.31 to 0.45; p=0.712). Similarly, neither elective nor non-elective caesarean section were associated with general cognitive ability in sibling analyses.
Conclusion: Birth by caesarean section is weakly associated with a lower general cognitive ability in young adult males. However, the magnitude of this association is not clinically relevant and seems to be largely explained by familial factors shared between siblings.
Clinical implication: Clinicians and gravidas ought not to be concerned that the choice of mode of delivery will impact offspring cognitive ability.
背景:剖宫产与子代认知能力的关系已有报道,但资料有限,需要大规模研究。目的:探讨分娩方式与一般认知能力的关系。方法:采用瑞典基于人口的登记系统,对1973年至1987年出生、2006年以前应征入伍的579244名单胎男性进行队列研究。他们的分娩方式是从瑞典医疗出生登记处获得的。结果测量是在18岁左右服兵役时进行的标准化一般认知测试(平均值100,标准差15)。结果:剖腹产出生的男性比顺产出生的男性表现更差(平均得分99.3比100.1;调整平均差-0.84;95% CI -0.97 ~ -0.72;结论:剖宫产与年轻成年男性较低的一般认知能力弱相关。然而,这种关联的程度与临床无关,似乎主要由兄弟姐妹之间共有的家族因素来解释。临床意义:临床医生和孕妇不应该担心分娩方式的选择会影响后代的认知能力。
{"title":"Caesarean section and its relationship to offspring general cognitive ability: a registry-based cohort study of half a million young male adults.","authors":"Viktor H Ahlqvist, Lucas D Ekström, Egill Jónsson-Bachmann, Per Tynelius, Paul Madley-Dowd, Martin Neovius, Cecilia Magnusson, Daniel Berglind","doi":"10.1136/ebmental-2021-300307","DOIUrl":"https://doi.org/10.1136/ebmental-2021-300307","url":null,"abstract":"<p><strong>Background: </strong>A relationship between caesarean section and offspring cognitive ability has been described, but data are limited, and a large-scale study is needed.</p><p><strong>Objective: </strong>To determine the relationship between mode of delivery and general cognitive ability.</p><p><strong>Methods: </strong>A cohort of 579 244 singleton males, born between 1973 and 1987 who conscripted before 2006, were identified using the Swedish population-based registries. Their mode of delivery was obtained from the Swedish Medical Birth registry. The outcome measure was a normalised general cognitive test battery (mean 100, SD 15) performed at military conscription at around age 18.</p><p><strong>Findings: </strong>Males born by caesarean section performed poorer compared with those born vaginally (mean score 99.3 vs 100.1; adjusted mean difference -0.84; 95% CI -0.97 to -0.72; p<0.001). Both those born by elective (99.3 vs 100.2; -0.92; 95% CI -1.24 to -0.60; p<0.001) and non-elective caesarean section (99.2 vs 100.2; -1.03; 95% CI -1.34 to -0.72; p=0.001), performed poorer than those born vaginally. In sibling analyses, the association was attenuated to the null (100.9 vs 100.8; 0.07; 95% CI -0.31 to 0.45; p=0.712). Similarly, neither elective nor non-elective caesarean section were associated with general cognitive ability in sibling analyses.</p><p><strong>Conclusion: </strong>Birth by caesarean section is weakly associated with a lower general cognitive ability in young adult males. However, the magnitude of this association is not clinically relevant and seems to be largely explained by familial factors shared between siblings.</p><p><strong>Clinical implication: </strong>Clinicians and gravidas ought not to be concerned that the choice of mode of delivery will impact offspring cognitive ability.</p>","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":" ","pages":"7-14"},"PeriodicalIF":5.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39407738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Question: Suicide is a global public and mental health problem. The effectiveness of social support interventions has not been widely demonstrated in the prevention of suicide. We aimed to describe the methods of social support interventions in preventing suicide and examine the efficacy of them.
Study selection and analysis: We searched literature databases and conducted clinical trials. The inclusion criteria for the summary of intervention methods were as follows: (1) studies aimed at preventing suicide through method(s) that directly provide social support; (2) use of one or more method(s) to directly provide social support. The additional inclusion criteria for meta-analysis on the efficacy of these interventions included: (1) suicide, suicide attempt or social support-related outcome was measured; (2) randomised controlled trial design and (3) using social support intervention as the main/only method.
Findings: In total, 22 656 records and 185 clinical trials were identified. We reviewed 77 studies in terms of intervention methods, settings, support providers and support recipients. There was a total of 18 799 person-years among the ten studies measuring suicide. The number of suicides was significantly reduced in the intervention group (risk ratio (RR)=0.48, 95% CI 0.27 to 0.85). In 14 studies with a total of 14 469 person-years, there was no significant reduction of suicide attempts in the overall pooled RR of 0.88 (95% CI 0.73 to 1.07).
Conclusions: Social support interventions were recommended as a suicide prevention strategy for those with elevated suicide risk.
问:自杀是一个全球性的公共和精神卫生问题。社会支持干预在预防自杀方面的有效性尚未得到广泛证明。我们的目的是描述预防自杀的社会支持干预方法,并检验其有效性。研究选择与分析:检索文献数据库并进行临床试验。干预方法总结的纳入标准为:(1)通过直接提供社会支持的方法预防自杀的研究;(2)使用一种或多种方法直接提供社会支持。对这些干预措施效果进行meta分析的附加纳入标准包括:(1)测量自杀、自杀未遂或社会支持相关的结果;(2)随机对照试验设计;(3)以社会支持干预为主要/唯一方法。结果:共纳入22 656份记录和185项临床试验。我们回顾了77项关于干预方法、设置、支持提供者和支持接受者的研究。在这10项研究中,总共有18799人年自杀。干预组的自杀人数显著减少(风险比(RR)=0.48, 95% CI 0.27 ~ 0.85)。在14项共14469人年的研究中,自杀企图没有显著减少,总合并RR为0.88 (95% CI 0.73至1.07)。结论:社会支持干预被推荐为自杀风险高的自杀预防策略。
{"title":"Methods and efficacy of social support interventions in preventing suicide: a systematic review and meta-analysis.","authors":"Xiaofei Hou, Jiali Wang, Jing Guo, Xinxu Zhang, Jiahai Liu, Linmao Qi, Liang Zhou","doi":"10.1136/ebmental-2021-300318","DOIUrl":"https://doi.org/10.1136/ebmental-2021-300318","url":null,"abstract":"<p><strong>Question: </strong>Suicide is a global public and mental health problem. The effectiveness of social support interventions has not been widely demonstrated in the prevention of suicide. We aimed to describe the methods of social support interventions in preventing suicide and examine the efficacy of them.</p><p><strong>Study selection and analysis: </strong>We searched literature databases and conducted clinical trials. The inclusion criteria for the summary of intervention methods were as follows: (1) studies aimed at preventing suicide through method(s) that directly provide social support; (2) use of one or more method(s) to directly provide social support. The additional inclusion criteria for meta-analysis on the efficacy of these interventions included: (1) suicide, suicide attempt or social support-related outcome was measured; (2) randomised controlled trial design and (3) using social support intervention as the main/only method.</p><p><strong>Findings: </strong>In total, 22 656 records and 185 clinical trials were identified. We reviewed 77 studies in terms of intervention methods, settings, support providers and support recipients. There was a total of 18 799 person-years among the ten studies measuring suicide. The number of suicides was significantly reduced in the intervention group (risk ratio (RR)=0.48, 95% CI 0.27 to 0.85). In 14 studies with a total of 14 469 person-years, there was no significant reduction of suicide attempts in the overall pooled RR of 0.88 (95% CI 0.73 to 1.07).</p><p><strong>Conclusions: </strong>Social support interventions were recommended as a suicide prevention strategy for those with elevated suicide risk.</p>","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":" ","pages":"29-35"},"PeriodicalIF":5.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/48/ebmental-2021-300318.PMC8788249.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39817377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01Epub Date: 2021-07-19DOI: 10.1136/ebmental-2021-300277
Jenny Lou Barican, Donna Yung, Christine Schwartz, Yufei Zheng, Katholiki Georgiades, Charlotte Waddell
Question: Mental disorders typically start in childhood and persist, causing high individual and collective burdens. To inform policymaking to address children's mental health in high-income countries we aimed to identify updated data on disorder prevalence.
Methods: We identified epidemiological studies reporting mental disorder prevalence in representative samples of children aged 18 years or younger-including a range of disorders and ages and assessing impairment (searching January 1990 through February 2021). We extracted associated service-use data where studies assessed this. We conducted meta-analyses using a random effects logistic model (using R metafor package).
Findings: Fourteen studies in 11 countries met inclusion criteria, published from 2003 to 2020 with a pooled sample of 61 545 children aged 4-18 years, including eight reporting service use. (All data were collected pre-COVID-19.) Overall prevalence of any childhood mental disorder was 12.7% (95% CI 10.1% to 15.9%; I2=99.1%). Significant heterogeneity pertained to diagnostic measurement and study location. Anxiety (5.2%), attention-deficit/hyperactivity (3.7%), oppositional defiant (3.3%), substance use (2.3%), conduct (1.3%) and depressive (1.3%) disorders were the most common. Among children with mental disorders, only 44.2% (95% CI 37.6% to 50.9%) received any services for these conditions.
Conclusions: An estimated one in eight children have mental disorders at any given time, causing symptoms and impairment, therefore requiring treatment. Yet even in high-income countries, most children with mental disorders are not receiving services for these conditions. We discuss the implications, particularly the need to substantially increase public investments in effective interventions. We also discuss the policy urgency, given the emerging increases in childhood mental health problems since the onset of the COVID-19 pandemic (PROSPERO CRD42020157262).
问题:精神障碍通常始于儿童时期并持续存在,造成个人和集体的沉重负担。为了为高收入国家儿童心理健康问题的政策制定提供信息,我们旨在确定疾病患病率的最新数据。方法:我们确定了流行病学研究,报告了18岁或以下儿童的代表性样本中精神障碍的患病率,包括一系列疾病和年龄,并评估了损害(检索时间为1990年1月至2021年2月)。我们提取了相关的服务使用数据,研究评估了这一点。我们使用随机效应逻辑模型(使用R元软件包)进行了元分析。结果:11个国家的14项研究符合纳入标准,发表于2003年至2020年,汇总样本为61,545名4-18岁儿童,其中8项报告了服务使用情况。(所有数据均在covid -19之前收集。)儿童精神障碍的总体患病率为12.7% (95% CI 10.1%至15.9%;I2 = 99.1%)。显著的异质性与诊断测量和研究地点有关。焦虑(5.2%)、注意缺陷/多动(3.7%)、对立违抗(3.3%)、物质使用(2.3%)、行为(1.3%)和抑郁(1.3%)障碍最为常见。在患有精神障碍的儿童中,只有44.2% (95% CI 37.6%至50.9%)接受了针对这些疾病的任何服务。结论:估计每八个儿童中就有一个在任何时候患有精神障碍,造成症状和损害,因此需要治疗。然而,即使在高收入国家,大多数患有精神障碍的儿童也没有得到针对这些疾病的服务。我们讨论了其影响,特别是需要大幅增加对有效干预措施的公共投资。鉴于自2019冠状病毒病大流行开始以来儿童心理健康问题出现增加,我们还讨论了政策紧迫性(PROSPERO CRD42020157262)。
{"title":"Prevalence of childhood mental disorders in high-income countries: a systematic review and meta-analysis to inform policymaking.","authors":"Jenny Lou Barican, Donna Yung, Christine Schwartz, Yufei Zheng, Katholiki Georgiades, Charlotte Waddell","doi":"10.1136/ebmental-2021-300277","DOIUrl":"https://doi.org/10.1136/ebmental-2021-300277","url":null,"abstract":"<p><strong>Question: </strong>Mental disorders typically start in childhood and persist, causing high individual and collective burdens. To inform policymaking to address children's mental health in high-income countries we aimed to identify updated data on disorder prevalence.</p><p><strong>Methods: </strong>We identified epidemiological studies reporting mental disorder prevalence in representative samples of children aged 18 years or younger-including a range of disorders and ages and assessing impairment (searching January 1990 through February 2021). We extracted associated service-use data where studies assessed this. We conducted meta-analyses using a random effects logistic model (using R metafor package).</p><p><strong>Findings: </strong>Fourteen studies in 11 countries met inclusion criteria, published from 2003 to 2020 with a pooled sample of 61 545 children aged 4-18 years, including eight reporting service use. (All data were collected pre-COVID-19.) Overall prevalence of any childhood mental disorder was 12.7% (95% CI 10.1% to 15.9%; I<sup>2</sup>=99.1%). Significant heterogeneity pertained to diagnostic measurement and study location. Anxiety (5.2%), attention-deficit/hyperactivity (3.7%), oppositional defiant (3.3%), substance use (2.3%), conduct (1.3%) and depressive (1.3%) disorders were the most common. Among children with mental disorders, only 44.2% (95% CI 37.6% to 50.9%) received any services for these conditions.</p><p><strong>Conclusions: </strong>An estimated one in eight children have mental disorders at any given time, causing symptoms and impairment, therefore requiring treatment. Yet even in high-income countries, most children with mental disorders are not receiving services for these conditions. We discuss the implications, particularly the need to substantially increase public investments in effective interventions. We also discuss the policy urgency, given the emerging increases in childhood mental health problems since the onset of the COVID-19 pandemic (PROSPERO CRD42020157262).</p>","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":" ","pages":"36-44"},"PeriodicalIF":5.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/ebmental-2021-300277","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39200714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01Epub Date: 2021-09-06DOI: 10.1136/ebmental-2021-300262
Elizabeth Wenzel, Beatriz Penalver Bernabe, Shannon Dowty, Unnathi Nagelli, Lacey Pezley, Robert Gibbons, Pauline Maki
Background: Compared with traditional screening questionnaires, computerised adaptive tests for severity of depression (CAT-DI) and computerised adaptive diagnostic modules for depression (CAD-MDD) show improved precision in screening for major depressive disorder. CAT measures have been tailored to perinatal women but have not been studied in low-income women of colour despite high rates of perinatal depression (PND).
Objective: This study aimed to examine the concordance between CAT and traditional measures of depression in a sample of primarily low-income black and Latina women.
Methods: In total, 373 women (49% black; 29% Latina) completed the Patient Health Questionnaire-9 (PHQ-9), CAD-MDD and CAT-DI at 845 visits across pregnancy and postpartum. We examined the concordance between continuous CAT-DI and PHQ-9 scores and between binary measures of PND diagnosis on CAD-MDD and the PHQ-9 (cut-off score >10). We examined cases with a positive PND diagnosis on the CAD-MDD but not on the PHQ-9 ('missed' cases) to determine whether clinic notes were consistent with CAD-MDD results.
Findings: CAT-DI and PHQ-9 scores were significantly associated (concordance correlation coefficient=0.67; 95% CI 0.58 to 0.74). CAD-MDD detected 5% more case of PND compared with PHQ-9 (p<0.001). The average per-visit rate of PND was 14.4% (14.5% in blacks, 14.9% in Latinas) on the CAD-MDD, and 9.5% (9.8% in blacks, 8.8% in Latinas) on the PHQ-9. Clinical notes were available on 60% of 'missed' cases and validated CAD-MDD PND diagnosis in 89% of cases.
Conclusions: CAD-MDD detected 5% more cases of PND in women of colour compared with traditional tests, and the majority of these cases were verified by clinician notes.
Clinical implications: Use of CAT in routine clinic care may address health disparities in PND screening.
背景:与传统的筛查问卷相比,计算机化抑郁严重程度适应性测试(CAT-DI)和计算机化抑郁适应性诊断模块(CAD-MDD)在筛查重度抑郁障碍方面显示出更高的准确性。尽管围产期抑郁症(PND)的发生率很高,但CAT措施是为围产期妇女量身定制的,但尚未对有色人种的低收入妇女进行研究。目的:本研究旨在检验在主要是低收入黑人和拉丁裔妇女的样本中,CAT和传统的抑郁测量之间的一致性。方法:共有373名妇女(49%黑人,29%拉丁裔)在怀孕和产后的845次就诊中完成了患者健康问卷-9 (PHQ-9)、CAD-MDD和CAT-DI。我们检查了连续CAT-DI和PHQ-9评分之间的一致性,以及CAD-MDD的PND诊断的二元测量与PHQ-9之间的一致性(截止评分bbb10)。我们检查了在CAD-MDD上诊断为PND阳性但在PHQ-9上没有诊断的病例(“遗漏”病例),以确定临床记录是否与CAD-MDD结果一致。结果:CAT-DI和PHQ-9评分显著相关(一致性相关系数=0.67;95% CI 0.58 ~ 0.74)。与PHQ-9相比,CAD-MDD检测出的PND病例多5%(结论:与传统检测相比,CAD-MDD在有色人种女性中检测出的PND病例多5%,这些病例中的大多数得到了临床医生的证实。临床意义:在常规临床护理中使用CAT可以解决PND筛查中的健康差异。
{"title":"Using computerised adaptive tests to screen for perinatal depression in underserved women of colour.","authors":"Elizabeth Wenzel, Beatriz Penalver Bernabe, Shannon Dowty, Unnathi Nagelli, Lacey Pezley, Robert Gibbons, Pauline Maki","doi":"10.1136/ebmental-2021-300262","DOIUrl":"10.1136/ebmental-2021-300262","url":null,"abstract":"<p><strong>Background: </strong>Compared with traditional screening questionnaires, computerised adaptive tests for severity of depression (CAT-DI) and computerised adaptive diagnostic modules for depression (CAD-MDD) show improved precision in screening for major depressive disorder. CAT measures have been tailored to perinatal women but have not been studied in low-income women of colour despite high rates of perinatal depression (PND).</p><p><strong>Objective: </strong>This study aimed to examine the concordance between CAT and traditional measures of depression in a sample of primarily low-income black and Latina women.</p><p><strong>Methods: </strong>In total, 373 women (49% black; 29% Latina) completed the Patient Health Questionnaire-9 (PHQ-9), CAD-MDD and CAT-DI at 845 visits across pregnancy and postpartum. We examined the concordance between continuous CAT-DI and PHQ-9 scores and between binary measures of PND diagnosis on CAD-MDD and the PHQ-9 (cut-off score >10). We examined cases with a positive PND diagnosis on the CAD-MDD but not on the PHQ-9 ('missed' cases) to determine whether clinic notes were consistent with CAD-MDD results.</p><p><strong>Findings: </strong>CAT-DI and PHQ-9 scores were significantly associated (concordance correlation coefficient=0.67; 95% CI 0.58 to 0.74). CAD-MDD detected 5% more case of PND compared with PHQ-9 (p<0.001). The average per-visit rate of PND was 14.4% (14.5% in blacks, 14.9% in Latinas) on the CAD-MDD, and 9.5% (9.8% in blacks, 8.8% in Latinas) on the PHQ-9. Clinical notes were available on 60% of 'missed' cases and validated CAD-MDD PND diagnosis in 89% of cases.</p><p><strong>Conclusions: </strong>CAD-MDD detected 5% more cases of PND in women of colour compared with traditional tests, and the majority of these cases were verified by clinician notes.</p><p><strong>Clinical implications: </strong>Use of CAT in routine clinic care may address health disparities in PND screening.</p>","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":"25 1","pages":"23-28"},"PeriodicalIF":11.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792164/pdf/ebmental-2021-300262.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10293306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01DOI: 10.1136/ebmental-2021-300278
Tasnim Hamza, Toshi A Furukawa, Nicola Orsini, Andrea Cipriani, Georgia Salanti
Objective: The current practice in meta-analysis of the effects of psychopharmacological interventions ignors the administered dose or restricts the analysis in a dose range. This may introduce unnecessary uncertainty and heterogeneity. Methods have been developed to integrate the dose-effect models in meta-analysis.
Methods: We describe the two-stage and the one-stage models to conduct a dose-effect meta-analysis using common or random effects methods. We illustrate the methods on a dataset of selective serotonin reuptake inhibitor antidepressants. The dataset comprises 60 randomised controlled trials. The dose-effect is measured on an odds ratio scale and is modelled using restricted cubic splines to detect departure from linearity.
Results: The estimated summary curve indicates that the probability of response increases up to 30 mg/day of fluoxetine-equivalent which results in reaching 50% probability to respond. Beyond 40 mg/day, no further increase in the response is observed. The one-stage model includes all studies, resulting in slightly less uncertainty than the two-stage model where only part of the data is analysed.
Conclusions: The dose-effect meta-analysis enables clinicians to understand how the effect of a drug changes as a function of its dose. Such analysis should be conducted in practice using the one-stage model that incorporates evidence from all available studies.
{"title":"Dose-effect meta-analysis for psychopharmacological interventions using randomised data.","authors":"Tasnim Hamza, Toshi A Furukawa, Nicola Orsini, Andrea Cipriani, Georgia Salanti","doi":"10.1136/ebmental-2021-300278","DOIUrl":"https://doi.org/10.1136/ebmental-2021-300278","url":null,"abstract":"<p><strong>Objective: </strong>The current practice in meta-analysis of the effects of psychopharmacological interventions ignors the administered dose or restricts the analysis in a dose range. This may introduce unnecessary uncertainty and heterogeneity. Methods have been developed to integrate the dose-effect models in meta-analysis.</p><p><strong>Methods: </strong>We describe the two-stage and the one-stage models to conduct a dose-effect meta-analysis using common or random effects methods. We illustrate the methods on a dataset of selective serotonin reuptake inhibitor antidepressants. The dataset comprises 60 randomised controlled trials. The dose-effect is measured on an odds ratio scale and is modelled using restricted cubic splines to detect departure from linearity.</p><p><strong>Results: </strong>The estimated summary curve indicates that the probability of response increases up to 30 mg/day of fluoxetine-equivalent which results in reaching 50% probability to respond. Beyond 40 mg/day, no further increase in the response is observed. The one-stage model includes all studies, resulting in slightly less uncertainty than the two-stage model where only part of the data is analysed.</p><p><strong>Conclusions: </strong>The dose-effect meta-analysis enables clinicians to understand how the effect of a drug changes as a function of its dose. Such analysis should be conducted in practice using the one-stage model that incorporates evidence from all available studies.</p>","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":"25 1","pages":"1-6"},"PeriodicalIF":5.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231575/pdf/ebmental-2021-300278.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10270456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-01DOI: 10.1136/ebmental-2021-300411
Catherine Henshall, Helen Jones, Tanya Smith, Andrea Cipriani
Researchactive clinical services have lower mortality rates and produce higher quality care outcomes, however, recruiting participants to clinical research in the National Health System (NHS) remains challenging. A recent study, assessing the feasibility of clinical staff electronically documenting patient consent to discuss research participation, indicated very low patient uptake, limiting its effectiveness as a strategy for improving access to research. A followon study comparing this ‘optin’ approach with an ‘optout’ approach, whereby patients are informed about research opportunities unless they indicate otherwise, found that patients and staff favoured an ‘optout’ approach and wanted research to be more accessible. Subsequently, in August 2021, Count me In was developed and launched within Oxford Health NHS Foundation Trust adult and older adult mental health services. Count Me In is an optout initiative and a 12month implementation study, aiming to promote inclusivity by enabling greater equity of information provision for marginalised groups (including Black, Asian and minority ethnic groups, older adults, people with physical and mental disabilities, refugees and asylum seekers), rather than relying on clinicianled recruitment. It was developed in consultation with our Caldicott Guardian and Head of Information Governance to ensure correct handling of patient data and to differentiate the initiative from ‘national data optout’. A robust communications plan raised awareness of the initiative (https://www. oxfordhealth.nhs.uk/publication/countme-in/). Patient contact preferences and research involvement are documented on the electronic patient record. Preliminary findings illustrate that in just over 3 months, 8824 patients became contactable through Count Me In, a 400% increase on the number previously contactable through the ‘standard’ optin. Only 120 patients have opted out of contact. Of 234 potentially eligible patients contacted about specific research studies, 46 (19.6%) consented to participate. Inclusivity across age, gender, ethnicity and diagnostic group is being monitored and early evidence signals positive changes in equity of research access. For instance, the Count Me In cohort now represents patients across 62 of the 70 diagnostic groups represented in the Trust’s caseload, in comparison to only 44 groups represented using the standard ‘optin’ approach. A full evaluation at the end of the 12month implementation phase will highlight trends and changes in research activity, while also allowing for process modifications to be made before the initiative is rolled out across the country. The ultimate aim is to extend Count Me In to as many NHS Trusts as possible, embedding research within routine patient care and promoting inclusivity by ensuring that research opportunities are offered to all patients with mental health issues, regardless of diagnosis or how well known they are to clinicians.
{"title":"Promoting inclusivity by ensuring that all patients with mental health issues are offered research opportunities in the NHS.","authors":"Catherine Henshall, Helen Jones, Tanya Smith, Andrea Cipriani","doi":"10.1136/ebmental-2021-300411","DOIUrl":"https://doi.org/10.1136/ebmental-2021-300411","url":null,"abstract":"Researchactive clinical services have lower mortality rates and produce higher quality care outcomes, however, recruiting participants to clinical research in the National Health System (NHS) remains challenging. A recent study, assessing the feasibility of clinical staff electronically documenting patient consent to discuss research participation, indicated very low patient uptake, limiting its effectiveness as a strategy for improving access to research. A followon study comparing this ‘optin’ approach with an ‘optout’ approach, whereby patients are informed about research opportunities unless they indicate otherwise, found that patients and staff favoured an ‘optout’ approach and wanted research to be more accessible. Subsequently, in August 2021, Count me In was developed and launched within Oxford Health NHS Foundation Trust adult and older adult mental health services. Count Me In is an optout initiative and a 12month implementation study, aiming to promote inclusivity by enabling greater equity of information provision for marginalised groups (including Black, Asian and minority ethnic groups, older adults, people with physical and mental disabilities, refugees and asylum seekers), rather than relying on clinicianled recruitment. It was developed in consultation with our Caldicott Guardian and Head of Information Governance to ensure correct handling of patient data and to differentiate the initiative from ‘national data optout’. A robust communications plan raised awareness of the initiative (https://www. oxfordhealth.nhs.uk/publication/countme-in/). Patient contact preferences and research involvement are documented on the electronic patient record. Preliminary findings illustrate that in just over 3 months, 8824 patients became contactable through Count Me In, a 400% increase on the number previously contactable through the ‘standard’ optin. Only 120 patients have opted out of contact. Of 234 potentially eligible patients contacted about specific research studies, 46 (19.6%) consented to participate. Inclusivity across age, gender, ethnicity and diagnostic group is being monitored and early evidence signals positive changes in equity of research access. For instance, the Count Me In cohort now represents patients across 62 of the 70 diagnostic groups represented in the Trust’s caseload, in comparison to only 44 groups represented using the standard ‘optin’ approach. A full evaluation at the end of the 12month implementation phase will highlight trends and changes in research activity, while also allowing for process modifications to be made before the initiative is rolled out across the country. The ultimate aim is to extend Count Me In to as many NHS Trusts as possible, embedding research within routine patient care and promoting inclusivity by ensuring that research opportunities are offered to all patients with mental health issues, regardless of diagnosis or how well known they are to clinicians.","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":"25 1","pages":"e1"},"PeriodicalIF":5.2,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231587/pdf/ebmental-2021-300411.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10582051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}